isradipine Side Effects
Also known as: DynaCirc
Analysis of 541 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
541
Death-Related
61
11.3% of reports
Hospitalizations
291
53.8% of reports
Top Indication
Hypertension
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 61 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 16 |
| COMPLETED SUICIDE | 8 |
| DIVERTICULITIS INTESTINAL PERFORATED | 8 |
| HYPERTENSION | 6 |
| CARDIO-RESPIRATORY ARREST | 5 |
| FATIGUE | 5 |
| PYREXIA | 5 |
| THROMBOCYTOPENIA | 5 |
| ABDOMINAL PAIN | 4 |
| ASTHENIA | 4 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 4 |
| TOXICITY TO VARIOUS AGENTS | 4 |
| ALANINE AMINOTRANSFERASE INCREASED | 3 |
| ASCITES | 3 |
| CARDIAC ARREST | 3 |
| CONFUSIONAL STATE | 3 |
| COORDINATION ABNORMAL | 3 |
| CYTOKINE RELEASE SYNDROME | 3 |
| DRUG HYPERSENSITIVITY | 3 |
| DRUG INTERACTION | 3 |
Reactions in Hospitalization Reports
Top reactions in 291 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INTERACTION | 25 |
| ACUTE KIDNEY INJURY | 22 |
| HYPERTENSION | 21 |
| DYSPNOEA | 18 |
| TUBULOINTERSTITIAL NEPHRITIS | 18 |
| DRUG INEFFECTIVE | 17 |
| OFF LABEL USE | 17 |
| CHRONIC KIDNEY DISEASE | 16 |
| ASTHENIA | 15 |
| DIARRHOEA | 15 |
| DRUG-INDUCED LIVER INJURY | 15 |
| NAUSEA | 14 |
| PYREXIA | 14 |
| RENAL FAILURE | 13 |
| VOMITING | 12 |
| HYPOTENSION | 11 |
| ABDOMINAL PAIN | 10 |
| FALL | 10 |
| MALAISE | 9 |
| METABOLIC ACIDOSIS | 9 |
Nearby — Related Medications
What the FAERS Data Reveals About isradipine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 541 voluntary reports linked to isradipine and its brand equivalents (DynaCirc), spanning 2004 through 2025. Of those, 61 (11.3%) listed death as an outcome and 291 (53.8%) involved hospitalization. The most common indication reported alongside adverse events was Hypertension.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 55% were female and 45% male; age distribution skews toward 75+, with 95 reports in that bracket. The single most reported reaction is drug ineffective with 35 submissions, followed by drug interaction and dyspnoea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.